Terns Pharmaceuticals Statistics
Total Valuation
TERN has a market cap or net worth of $240.94 million. The enterprise value is -$110.20 million.
Important Dates
The last earnings date was Thursday, March 20, 2025, after market close.
| Earnings Date | Mar 20, 2025 |
| Ex-Dividend Date | n/a |
Share Statistics
TERN has 87.30 million shares outstanding. The number of shares has increased by 11.58% in one year.
| Current Share Class | 87.30M |
| Shares Outstanding | 87.30M |
| Shares Change (YoY) | +11.58% |
| Shares Change (QoQ) | +17.25% |
| Owned by Insiders (%) | 0.75% |
| Owned by Institutions (%) | 64.78% |
| Float | 53.71M |
Valuation Ratios
| PE Ratio | n/a |
| Forward PE | n/a |
| PS Ratio | n/a |
| Forward PS | n/a |
| PB Ratio | 0.74 |
| P/TBV Ratio | 0.71 |
| P/FCF Ratio | n/a |
| P/OCF Ratio | n/a |
| PEG Ratio | n/a |
Financial Ratio HistoryEnterprise Valuation
| EV / Earnings | n/a |
| EV / Sales | n/a |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | n/a |
Financial Position
The company has a current ratio of 23.14, with a Debt / Equity ratio of 0.00.
| Current Ratio | 23.14 |
| Quick Ratio | 22.89 |
| Debt / Equity | 0.00 |
| Debt / EBITDA | n/a |
| Debt / FCF | n/a |
| Interest Coverage | n/a |
Financial Efficiency
Return on equity (ROE) is -29.56% and return on invested capital (ROIC) is -21.11%.
| Return on Equity (ROE) | -29.56% |
| Return on Assets (ROA) | -20.13% |
| Return on Invested Capital (ROIC) | -21.11% |
| Return on Capital Employed (ROCE) | -29.25% |
| Revenue Per Employee | n/a |
| Profits Per Employee | -$1.51M |
| Employee Count | 59 |
| Asset Turnover | n/a |
| Inventory Turnover | n/a |
Taxes
In the past 12 months, TERN has paid $260,000 in taxes.
| Income Tax | 260,000 |
| Effective Tax Rate | n/a |
Stock Price Statistics
The stock price has decreased by -57.93% in the last 52 weeks. The beta is -0.31, so TERN's price volatility has been lower than the market average.
| Beta (5Y) | -0.31 |
| 52-Week Price Change | -57.93% |
| 50-Day Moving Average | 3.87 |
| 200-Day Moving Average | 6.47 |
| Relative Strength Index (RSI) | 30.06 |
| Average Volume (20 Days) | 930,679 |
Short Selling Information
The latest short interest is 5.95 million, so 6.81% of the outstanding shares have been sold short.
| Short Interest | 5.95M |
| Short Previous Month | 6.19M |
| Short % of Shares Out | 6.81% |
| Short % of Float | 11.07% |
| Short Ratio (days to cover) | 5.57 |
Income Statement
| Revenue | n/a |
| Gross Profit | n/a |
| Operating Income | -101.87M |
| Pretax Income | -95.63M |
| Net Income | -88.85M |
| EBITDA | -101.55M |
| EBIT | -101.87M |
| Earnings Per Share (EPS) | -$1.12 |
Full Income StatementBalance Sheet
The company has $358.16 million in cash and $1.35 million in debt, giving a net cash position of $356.82 million or $4.09 per share.
| Cash & Cash Equivalents | 358.16M |
| Total Debt | 1.35M |
| Net Cash | 356.82M |
| Net Cash Per Share | $4.09 |
| Equity (Book Value) | 345.87M |
| Book Value Per Share | 3.97 |
| Working Capital | 346.46M |
Full Balance SheetCash Flow
In the last 12 months, operating cash flow was -$70.02 million and capital expenditures -$42,000, giving a free cash flow of -$70.06 million.
| Operating Cash Flow | -70.02M |
| Capital Expenditures | -42,000 |
| Free Cash Flow | -70.06M |
| FCF Per Share | -$0.80 |
Full Cash Flow StatementMargins
| Gross Margin | n/a |
| Operating Margin | n/a |
| Pretax Margin | n/a |
| Profit Margin | n/a |
| EBITDA Margin | n/a |
| EBIT Margin | n/a |
| FCF Margin | n/a |